{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,7,30]],"date-time":"2025-07-30T12:20:37Z","timestamp":1753878037203,"version":"3.41.2"},"reference-count":49,"publisher":"Wiley","issue":"8","license":[{"start":{"date-parts":[[2024,8,20]],"date-time":"2024-08-20T00:00:00Z","timestamp":1724112000000},"content-version":"vor","delay-in-days":19,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004325","name":"AstraZeneca","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004325","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["ascpt.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Clinical Translational Sci"],"published-print":{"date-parts":[[2024,8]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Association between measurable residual disease (MRD) and survival outcomes in chronic lymphocytic leukemia (CLL) has often been reported. However, limited quantitative analyses over large datasets have been undertaken to establish the predictive power of MRD. Here, we provide a comprehensive assessment of published MRD data to explore the utility of MRD in the prediction of progression\u2010free survival (PFS). We undertook two independent analyses, which leveraged available published data to address two complimentary questions. In the first, data from eight clinical trials was modeled via a meta\u2010regression approach, showing that median PFS can be predicted from undetectable MRD rates at 3\u20136\u2009months of post\u2010treatment. The resulting model can be used to predict the probability of technical success of a planned clinical trial in chemotherapy. In the second, we investigated the evidence for predicting PFS from competing MRD metrics, for example baseline value and instantaneous MRD value, via a joint modeling approach. Using data from four small studies, we found strong evidence that including MRD metrics in joint models improves predictions of PFS compared with not including them. This analysis suggests that incorporating MRD is likely to better inform individual progression predictions. It is therefore proposed that systematic MRD collection should be accompanied by modeling to generate algorithms that inform patients' progression.<\/jats:p>","DOI":"10.1111\/cts.13905","type":"journal-article","created":{"date-parts":[[2024,8,22]],"date-time":"2024-08-22T02:16:44Z","timestamp":1724293004000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Predicting progression\u2010free survival from measurable residual disease in chronic lymphocytic leukemia"],"prefix":"10.1111","volume":"17","author":[{"given":"Florencia A.","family":"Tettamanti","sequence":"first","affiliation":[{"name":"Clinical Pharmacology and Quantitative Pharmacology, CPSS, BioPharmaceuticals R&amp;D AstraZeneca  Cambridge UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Holly","family":"Kimko","sequence":"additional","affiliation":[{"name":"Clinical Pharmacology and Quantitative Pharmacology, CPSS, BioPharmaceuticals R&amp;D AstraZeneca  Gaithersburg Maryland USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shringi","family":"Sharma","sequence":"additional","affiliation":[{"name":"Clinical Pharmacology and Quantitative Pharmacology, CPSS, BioPharmaceuticals R&amp;D AstraZeneca  South San Francisco California USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giovanni","family":"Di\u00a0Veroli","sequence":"additional","affiliation":[{"name":"Clinical Pharmacology and Quantitative Pharmacology, CPSS, BioPharmaceuticals R&amp;D AstraZeneca  Cambridge UK"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2024,8,20]]},"reference":[{"key":"e_1_2_9_2_1","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.840616"},{"key":"e_1_2_9_3_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2015-06-651125"},{"key":"e_1_2_9_4_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clml.2019.03.014"},{"key":"e_1_2_9_5_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2011.36.9348"},{"key":"e_1_2_9_6_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(16)30051-1"},{"key":"e_1_2_9_7_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1313984"},{"key":"e_1_2_9_8_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2016-05-714162"},{"key":"e_1_2_9_9_1","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2013.099796"},{"key":"e_1_2_9_10_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.04.021"},{"key":"e_1_2_9_11_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2017-09-806398"},{"key":"e_1_2_9_12_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2017-06-792333"},{"key":"e_1_2_9_13_1","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.755549"},{"key":"e_1_2_9_14_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-018-0276-9"},{"key":"e_1_2_9_15_1","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2018.204891"},{"key":"e_1_2_9_16_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-019-5971-z"},{"issue":"8","key":"e_1_2_9_17_1","first-page":"440","article-title":"Venetoclax, the first bcl\u20102 inhibitor for use in patients with chronic lymphocytic leukemia","volume":"17","author":"Seymour J","year":"2019","journal-title":"Clin Adv Hematol Oncol"},{"key":"e_1_2_9_18_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.21.01181"},{"key":"e_1_2_9_19_1","doi-asserted-by":"publisher","DOI":"10.1002\/cpt.2005"},{"key":"e_1_2_9_20_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-22-0964"},{"key":"e_1_2_9_21_1","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2019.239566"},{"key":"e_1_2_9_22_1","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2288-12-9"},{"key":"e_1_2_9_23_1","doi-asserted-by":"publisher","DOI":"10.1136\/ebmental-2019-300117"},{"key":"e_1_2_9_24_1","doi-asserted-by":"publisher","DOI":"10.1111\/cts.12524"},{"key":"e_1_2_9_25_1","unstructured":"Antony 2019 France: Lixsoft SAS.Monolix version 2018R1.2018.http:\/\/lixoft.com\/products\/monolix\/."},{"key":"e_1_2_9_26_1","doi-asserted-by":"publisher","DOI":"10.1093\/bioinformatics\/btp619"},{"key":"e_1_2_9_27_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.tree.2010.04.001"},{"key":"e_1_2_9_28_1","unstructured":"MATLAB.Natick Massachusetts United States: The MathWorks Inc.2022.https:\/\/www.mathworks.com"},{"key":"e_1_2_9_29_1","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2288-11-139"},{"volume-title":"The Theory of Probability","year":"1961","author":"Jeffreys H","key":"e_1_2_9_30_1"},{"key":"e_1_2_9_31_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2013-05-502773"},{"key":"e_1_2_9_32_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2003-12-4321"},{"key":"e_1_2_9_33_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V126.23.1733.1733"},{"key":"e_1_2_9_34_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.18.01580"},{"key":"e_1_2_9_35_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-020-01009-z"},{"key":"e_1_2_9_36_1","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2013.52"},{"key":"e_1_2_9_37_1","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2008.96"},{"key":"e_1_2_9_38_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1541-0420.2012.01823.x"},{"key":"e_1_2_9_39_1","doi-asserted-by":"publisher","DOI":"10.1002\/psp4.12763"},{"key":"e_1_2_9_40_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10928-023-09853-z"},{"key":"e_1_2_9_41_1","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.03206-2020"},{"key":"e_1_2_9_42_1","doi-asserted-by":"publisher","DOI":"10.1097\/01.HS9.0000974604.64165.9a"},{"key":"e_1_2_9_43_1","doi-asserted-by":"publisher","DOI":"10.3390\/cancers13102468"},{"key":"e_1_2_9_44_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2016.67.1305"},{"key":"e_1_2_9_45_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.leu.2404584"},{"key":"e_1_2_9_46_1","unstructured":"U.S. Food and Drug Administration.Hematologic malignancies: regulatory considerations for use of minimal residual disease in development of drug and biological products for treatment.2020. FDA.https:\/\/www.fda.gov\/regulatory\u2010information\/search\u2010fda\u2010guidance\u2010documents\/hematologic\u2010malignancies\u2010regulatory\u2010considerations\u2010use\u2010minimal\u2010residual\u2010disease\u2010development\u2010drug\u2010and. Accessed 15 February 2024."},{"key":"e_1_2_9_47_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jclinepi.2022.03.009"},{"key":"e_1_2_9_48_1","doi-asserted-by":"publisher","DOI":"10.1093\/ckj\/sfaa024"},{"key":"e_1_2_9_49_1","doi-asserted-by":"publisher","DOI":"10.1111\/biom.12537"},{"issue":"1","key":"e_1_2_9_50_1","first-page":"1","article-title":"Explainable deep learning for tumor dynamic modeling and overall survival prediction using neural\u2010ODE npj","volume":"9","author":"Laurie M","year":"2023","journal-title":"Syst Biol Appl"}],"container-title":["Clinical and Translational Science"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ascpt.onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/cts.13905","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,8,29]],"date-time":"2024-08-29T05:28:00Z","timestamp":1724909280000},"score":1,"resource":{"primary":{"URL":"https:\/\/ascpt.onlinelibrary.wiley.com\/doi\/10.1111\/cts.13905"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8]]},"references-count":49,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2024,8]]}},"alternative-id":["10.1111\/cts.13905"],"URL":"https:\/\/doi.org\/10.1111\/cts.13905","archive":["Portico"],"relation":{},"ISSN":["1752-8054","1752-8062"],"issn-type":[{"type":"print","value":"1752-8054"},{"type":"electronic","value":"1752-8062"}],"subject":[],"published":{"date-parts":[[2024,8]]},"assertion":[{"value":"2024-02-27","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-07-12","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-08-20","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e13905"}}